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ABST RACT
The SARS-CoV-2 mutations that have occurred have alarmed the entire
medical community. Thus, global concerns have been expressed
regarding the transmission, pathogenicity and immune evasion of the
Omicron strain, which shares mutations with the variants of concern
Alpha, Beta, and Gamma strains. Still, Omicron transmission has
crossed numerous borders worldwide compared to other types of SARSCoV-2. The number of confirmed cases has increased and is reappearing
in India. Given the worrisome situation created by the Omicron
outbreak, scientists and postgraduates have had to make decisions about
current research programs at institutions around the globe. The Omicron
variants under development have significantly heightened worldwide
pandemic concerns. In this review, the authors will outline the molecular
features and efficacy of vaccination, highlight possible omicron impacts
on scientific research, and provide precautions, procedural guidelines for
organizing scientific meetings during a pandemic.

Introduction
The global World Health Organization (WHO) has
designated the coronavirus outbreak as a pandemic, the
SARS-CoV-2 Omicron variant (B.1.1.529) being one of
the most prevalent variants of concerns (VOCs) [1]. The
first genomic surveillance teams in South Africa and
Botswana found a new VOC after a rapid resurgence of
SARS-CoV-2 outbreaks in the Gauteng region of South
Africa [2]. Numerous VOCs have been found to have
similar alterations to Omicrons such as alpha and beta.
With more than twice as many mutated proteins in the
spike protein as the already highly contagious delta variant
[3], other viral replication-related proteins, such as two
non-structural proteins (NSP12, NSP14), show substantial
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variation across variants [4]. Omicron SARS-CoV-2 was
three times more infectious than SARS-CoV-2. The new
Omicron variant is found in 38 countries throughout the
world, including Hong Kong, Israel, Colombia, Australia,
Botswana, South Africa, Singapore, India, China, Saudi
Arabia, the US and other developing countries [5]. As 2022
draws to a close, people with vaccine-induced immunity
have surged and many of them believed the pandemic was
over. So far, 150 countries have closed schools,
universities and research institutes, affecting 80% of
students worldwide. Several countries have implemented
specific measures in university and research institutions.
which must be closed [6]. Reopening institutions in a
pandemic situation can cause concern and anxiety among
people [7]. This review article presents information on
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omicron characteristics, vaccine efficacy, and addresses
the implications of omicron outbreaks for academic
research.

Discussion
SARS-CoV-2 Omicron's (B.1.1.529) Havoc
The impact of the recent omicron growth in India on
academic research has yet to be assessed. One of the
longest periods of university, research and school closures
in the world has probably occurred in India compared to
other countries [7]. Omicron struck as the nation prepared
to start colleges, schools and research organizations and
regularize routine operations. As the system prepares to
deal with the omicron's various issues, the reopening of
institutions could be put on hold again. As before,
complications are more of a concern these days, especially
learning and mental health difficulties for researchers and
students. As a result of the current omicron outbreak in
India [8], there has been a significant rise in the number of
secondary school kids and Ph.D. researchers hospitalized
for Omicron infections, both in raw numbers and as a share
of all Omicron hospitalizations. However, it is unclear
whether these hospitalizations result from serious illnesses
or researchers who were treated for other reasons and
unintentionally found to be infected with COVID-19.
Apart from the direct implications, the indirect
consequences of omicron growth from closing research
institutions, closing universities and economic
consequences can exacerbate the world's physical,
emotional and social health problems [9]. Many nations
such as the US, Canada, Europe, the UK and the Middle
East (with Sinopharm) have launched immunization of
children and adolescents [10,11]. Two vaccines have
received approval from the Drug Controller General of
India: Covaxin, an inactivated vaccine for ages 18 and
above, and ZyCoV-D, a DNA-based vaccination for
children aged between 12 and 18. The Indian government
has stated that starting on January 3, 2022, all children and
adults aged 15 and older will get the Covaxin vaccine [12].
Since research has revealed the appearance of the omicron
after its peak, progress should be monitored over the
next few weeks.
Omicron's Structural Features
Omicron variant is derived from Pango lineage
B.1.1.529, and differs from the originating strain in 21
amino acids associated with the spike protein, mostly in the
receptor-binding domain (RBD) (residues 319–541)
[13,14]. SARS-CoV-2 has undergone a number of changes
that were not previously observed [15]. Mutations in the
spike (S) protein, where antibodies attach, contribute to the
increased infectivity and transmissibility of the Omicron
variant [16,17]. The Omicron S protein contains 30 amino
acid alterations, three deletions, and one small insertion
[18]. About half (15) of the amino acid alterations are in

the RBD [19]. The N501Y change is one of the most
important and Q498R has a stronger affinity for ACE-2
receptors than the other 15 RBD variants, thus indicating
its enhanced transmissibility [13,17]. Figure 1 shows the
domain layout of the 32 spike proteins identified in
Omicron, which contains more mutations than any other
Delta COVID-19 variant. These mutations include A67V,
T95I, Y145D, G339D, K417N, N440K, G446S, S477N,
T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H,
D614G and K618 [18]. Mutations at H655Y, N679K and
P681H in the S1S2 furin cleavage site of the omicron form
may enhance transmissibility [19]. A P681H mutation was
also detected in the alpha variant [20,21]. In the delta
variant, Q498R and N501Y alterations boosted ACE2
binding [22] in which this mutation increases SARS-CoV2 infectivity [23]. ACE-2 receptors are key factors in
COVID-19, which may cause organ failure severely [20].

Figure 1. A) The schematic diagram illustrating the
domain arrangement of the 32- spike protein found in
Omicron. B) The Cryo-EM structure of Omicron spike
protein in complex with human ACE2.
Symptoms, complications and diagnosis
Omicron showed modified spike proteins compared to
Delta variant COVID-19. The Delta variation (B.1.617.2)
has eight spike protein mutations, whereas the Omicron
variant (B.1.1.529) has 32 mutations. The delta variant was
identified in India in 2021, along with eight other
alterations [24]. The standard incubation time for the
previous virus was five days, while the new virus may have
a median incubation period of just two to three days [25].
Omicron symptoms include a runny nose, sore throat,
headache, mild-to-severe fatigue, sneezing, and night
sweats [25]. Fever, cough, and loss of taste/odor are far less
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common. Symptoms remain for several days before
disappearing. Omicron-positive patients have no
respiratory problems, and their saturation levels remained
normal. The biological and clinical characteristics o of the
Omicron are remarkably similar to the COVID-19
infections, several general characteristics being described
in Table 1. RT-PCR, high-throughput genome sequencing,
anti-viral immunoglobulin M (IgM) and G (IgG) antibody
testing, as well as lung X-ray (CT scan value) were used to
identify SARS-Covid-2 infection [32]. Both the SARSCoV-2 infection diagnostic tests have been authorized by
the FDA, including tests for PCR (also known as molecular
testing). This is the most often used method while the
another one is the antigen assay diagnostic test.
Table 1. The general characteristics of Omicron
Biological characteristics [25,26].
Virus

Single standard RNA
All SARS Originated from Bats, Civet
cats, Omicron originated from Gauteng,
Origin
South Africa
Omicron variant is more transmissible
than previous strains especially
Nosocomial, respiratory, Airborne and
Transmission
Zoonotic Transmission* and Aerosol
droplets through human to human
Spike protein
Contain 35 mutation on the spike protein
Dominance
Both male and female
Age of infected Known to be infecting younger individuals
individuals
more than previous strains
Incubation periods
2- 3days
Peak (Omicron variant is more
Spread mode
transmissible than previous strains)
Incidence
During (Nov- Jan) winter season

Clinical characteristics [27-29].
Head ache
Joint Pain
Fever
Chillness/Rigors
Malaise
Generalized
Myalgia
Drowsy

Mild
Mild
Moderate
Moderate
Mild
Moderate
Mild

Pulmonary Characteristics [30,31]
Cough
Shortness of
breath
Abdominal pain
Nausea and
Vomiting
Dyspnea
Diarrhea
Pneumonia
Hemoptysis
Acute Renal
failure
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Moderate
Mild
Mild
Mild
Mild
Mild
Further investigation is required
Further investigation is required
Further investigation is required

Role of Booster Vaccination
Omicron improves vaccine-induced immunity more
than delta variant. This is the most controversial issue
being discussed in the world at present. In vitro
investigations demonstrate that BNT162b2 and AZD1222
generate reduced neutralizing antibody titers against
Omicron [33,34]. Several vaccines such as mRNA-1273
(Moderna), Sputnik, Sinopharm, and Ad26.COV2.S
(Janssen) have had lower neutralizing antibody titers
against Omicron. Pfizer reported that after the third
BNT162b2 injection, the titer of neutralizing antibodies
was raised by 25-fold, reaching the level of two vaccination
doses to prevent the original viral strain [35]. Additionally,
the levels of neutralizing antibodies produced in response
to the Ad26.COV2.S vaccination was also increased. No
impact on the Omicron form was seen in an mRNA
investigation of the ChAdOx1immunization [36]. After the
second BNT162b2 immunization, the vaccine's
effectiveness dropped to 88% (CI: 64.9 percent – 95.8
percent) and steadily deteriorated over the next 2–9 weeks.
It also decreased from 48.5 to 34.2 percent (5%–58.7%)
from 10–14 weeks to 25 weeks after the second
immunization. The two BNT162b2 or AZD1222 vaccines
were ineffective in protecting against symptomatic illness
and have resulted in fewer hospitalizations for omicrons
[37]. During the omicron surge, two doses of BNT162b2
were 70% protective against hospitalization compared to
93% before the peak [38]. With the number of cases rising
and concerns about an omicron surge, India has also stated
that health care personnel, frontline employees, and people
over 60 would will start receiving booster doses from
January 10, 2022 [39]. Studies demonstrate that
heterologous boosters perform better than homologous
ones [40].
According to specific estimations, the Omicron
distribution in India may be quite different from other
countries. According to the worldwide data population,
fully and partially vaccinated globally are shown in Figure
2. Just 73% of India's population is fully vaccinated
including boosters, this percentage is much lower than the
global average of Only 73% of India's population is fully
vaccinated (including boosters), much lower than the
United Arab Emirates global average of 100% [41].
Omicron may spread quicker in India, highlighting the
urgent need to increase vaccine coverage. Despite the
FDA-approved COVID-19 vaccines' reduced efficacy
against variant viruses [42-48], they have been shown to
protect against significant illness, hospitalization, and
death [49-51].
On the other hand, sera from people who got the
vaccine showed that the Omicron variant was 40% less
effective at neutralizing the virus than the SARS-CoV-2
wild type [52]. Based on these results, the current COVID-
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19 vaccine might not work as well against the Omicron
variant as it does against other COVID-19 variants. As
there is no vaccine for Omicron, vaccines for SARS-CoV2 variants that include Omicron are used as a preventive
measure to make the disease less severe and less likely to
lead to death [53].

Figure 2. World wide data of fully vaccinated and
partially vaccinated for COVID -19 Vaccine

However, three critical concerns remain unanswered:
1) Will this variant lead to more severe and fatal diseases?
2) Will prior vaccination protect against this new variant?
3) Will previous medicines be effective against this new
variant?
The most critical issue is whether boosters are
necessary and beneficial. Price-justified? Omicron is now
widespread in the nations with the highest rates of booster
immunization (the United States, the United Kingdom, and
Europe). Still, cases have begun to decline considerably in
South Africa, where only 30% of the population has had
two doses of the vaccine.
Several studies demonstrate that a COVID-19 booster
dosage may maintain and improve vaccine effectiveness
[54]. Since India last manufactured a billion vaccine doses,
it can now analyze over one million samples each day [55].
Globally, the WHO is actively collaborating with
researchers to investigate the transmission, severity, and
effectiveness of Omicron vaccines and the availability of
clinical trials for the disease [56]. Table 2 shows the list of
vaccines approved in India b the WHO. Also, more
research is needed to find out how well COVID-19,
Omicron, and other variants in India work.

Table 2. The list of vaccines approved in India for COVID-19 by WHO
Name of the vaccine

Vaccine
type/Platform

Moderna: mRNA-1273

RNA

Pfizer-BioNTechBNT162b2

RNA

Ad26.COV2.S
(Johnson & Johnson):
AZD1222
(Oxford/AstraZeneca)
Covishield
(Serum Institute of
India)
Covaxin
COVAXIN
(Bharat biotech)

Genetically
modified Viral
vectors
Genetically
modified Viral
vectors
Genetically
modified Viral
vectors
Inactivated

Sinopharm

Inactivated

Sinovac: CoronaVac

Inactivated

Zyduscadila ZyCoV-D

DNA

Gamaleya Sputnik V

Genetically
modified Viral
vectors

Serum Institute of India
COVOVAX (Novavax
Protein subunit
formulation)

No of trials in
counties

No of the approved
countries

WHO
approved

Ref.

78

Yes

Baden et al. [57]

112

Yes

Tartof et al. [58]

16 trails in
18 countries

85

Yes

WHO [59]

50 trails in
23 countries

127

Yes

Voysey et al.
[60]

2 trails in 1
country

47

Yes

Voysey et al.
[60]

7 trails in 1
country

12

Yes

Madhi et al. [61]

72

Yes

Zhang et al. [62]

46

Yes

Jara et al. [63]

1

No

Momin et al.
[64]

74

No

Baraniuk et al.
[65]

33 trials in 8
countries
46 trails in
21 countries

9 trails in 10
countries
26 trails in 8
countries
5 trials in 1
country
22 trials in 7
countries
2 trails in 1
country

2

No

Serum Institute
of India Pvt. Ltd.
[66-68]
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Impact on biomedical research studies
Most developed countries have implemented strict
national isolation measures to stop viral transmission and
spread in response to the increase in omicron cases
worldwide. Similarly, India has also implemented state and
district-wise boarders' closure of universities, schools,
colleges, and research organizations, resulting in strict
limitations on people's mobility [69]. As a result,
universities and research institutions have been compelled
to carefully identify and allocate essential research
activities, while other industrial companies have been
completely suspended [70]. Basic scientific research often
involves wet lab work, making it difficult for scientists to
work from home such an activity that requires their
physical presence in the laboratory [71]. The Omicron
controversy had a negative influence on scientific research
on animals. In light of personnel shortages (caused by
disease and quarantine) and supply chain interruptions,
concerns have been expressed about the treatment of
laboratory animals [72]. Over a hundred rodents were
killed in an animal house lab at the Vinayaga Mission
Research Foundation. This scientifically valuable resource
might take years to rebuild [72]. In their study of
genetically modified organisms, scientists from the Max
Delbrück Center in Germany and Tsinghua University
killed more than a thousand mice and rats.
Disruption induced by a pandemic and time passage
rendered these organisms unsustainable in both
circumstances [73]. Conversely, during the pandemic
period, laboratories were instructed to scale down their
animal care by research groups, pharmaceutical
companies, and universities around the globe. As a result,
ethical questions were inevitably raised. Similarly, in
research involving the use of stem cells, researchers have
had similar difficulties. In the Aaruapdai Veedu medical
college and hospital cell culture lab, OG specialists, Ph.D.
students, and research scientists froze hundreds of cell
lines due to facility closures. After thawing, the
experimental cell line is analyzed at to ensure it is still
good. In addition, there is a risk that issues related to an
integrity breach may occur, which would affect any
application that follows [74].
Additionally, researchers may need to spend a lot of
time thawing materials. For labs to resume their preOmicron level of research, it can take months or even
years, and if there is damaged material it can take much
longer. Basic scientific research has also been affected by
supply restrictions. The majority of researchers need to use
personal protective equipment (PPE) to protect themselves
against hazards in the lab [75]. Numerous lab supplies,
including cell culture media and chemicals for RNA
extraction, have been documented to be short-handed [76].
When new and ongoing non-COVID-19 research is
stopped and more professionals move to COVID-19
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research, there is a growing fear that basic scientific
research on other important diseases, like cardiometabolic
disorders and cancer, could be hurt in a way that can't be
fixed [77].
Impact on life sciences studies
Omicron had a particularly devastating effect on earlycareer researchers (ECRs) and Ph.D. students [78].
Research budgets are generally limited, making both
parties' incomes highly susceptible to economic
fluctuations. Most Ph.D. students depend on fellowships
that last from one to four years. Additional tuition and
consumable research costs may be incurred due to time
wasted via the lack of productivity caused by omicron.
Short-term contracts of one to two years are anticipated
from ECRs.
Job applications may be negatively affected if
researchers cannot meet the goals outlined in their initial
research plan [78]. More than half of postdoctoral
researchers polled by Nature between June and July 2020
indicated anxiety about the COVID-19 pandemic's
influence on their future career prospects [79-81]. In
addition, many more variables have raised worries on
research aspects professional advancement, as follows:
• Due to university and research organization closures,
researchers may be unable to complete investigations
in time for publication.
• Many academic accomplishments remain unreported
owing to a lack of funding since their research output
has been used in funding decision.
• In a scientific meeting, many academics may lose key
career development opportunities for networking or
research dissemination as most global scientific
meetings move to a virtual platform. Also, young
researchers may feel especially exposed when they
share sensitive information and new ideas online.
• Employment closures and funding issues several
institutions are facing financial difficulties due to a
historic drop in foreign student enrollment and the
associated drop in university income. Many have
eliminated jobs and slowed or frozen hiring.
Globally, omicron and other viral variants have
complicated academic and professional work for many
scientists involved in research [82]. Many international
researchers are forced to limit or even abandon their studies
or jobs due to visa term restrictions [79]. Due to visa time
constraints, a group of researchers may have difficulty
acquiring a position on the following academic career
ladder, particularly if they desire to remain in their current
location [80]. Many international researchers have been
unable to take jobs abroad due to travel restrictions
imposed by the pandemic [79]. Figure 3 shows the overall
impact of Omicron on various academic research studies.

SARS-CoV-2 Omicron (B.1.1.529) variant; a systematic review

Precautions and Procedural Guidelines

Figure 3. Effects of the Omicron outbreak in academic
research
Impact on clinical studies
The omicron scenario will make it difficult for clinical
studies to meet their research and teaching commitments
and secure funding [83]. Omicron has also affected the
research industry, forcing scientists and researchers to
return to regular activities [84]. The lack of patient samples
hampered due to the impact of the pandemic. Clinicians do
not find any remarkable success in their regular research
and development activities because companies lack
scientific support, fewer specialists, and other equipment
and chemicals [85]. Ensure that participants are regularly
informed of any changes to the research protocol. For
current trials, concerns include electronic data recording
through telemedicine, phone interviews, or alternative sites
for assessment. Determine whether to revise the original
statistical analysis plan in light of potential missing data
(e.g., from missed study visits or study termination). There
is an urgent need to provide evidence-based suggestions for
clinical practices that can be impacted by strict and
effective Omicron infection control procedures [86]. So,
following the rapid advice guidelines approach and the
essential criteria of WHO guideline production, we
developed this recommendation. For research purposes,
this rapid mentoring guideline is for first-line scientists,
researchers, research students, and healthcare professionals
interested in the 2021 Omicron outbreak and learning more
quickly [80]. Clinical and researchers working on the
omicron pandemic outbreak period will benefit from our
assessment, which sees this rapid review opinion measure
as a sound scientific technique [71]. We address
technology in this guideline, organize meetings during
pandemic scenarios, and carry out current research projects
within the organization. We also provide guidelines for
physicians and researchers in preparation for their
scientific meetings and also guidance for medical
treatment. When it comes to creating future frontiers, they
will need to know how to tackle the current situation.

Requirements (Good Personal Hygiene Practices).
Aspiring clinicians should fulfill these minimum
requirements:
No employee with conjunctivitis, a severe cold, etc.,
will be not allowed in.
Each supervisor or department head shall monitor the
omicron and notify the research committee.
Avoid crowded areas and direct contact with
chronically ill or sick people.
Frequently clean your hands with soap (such as before
eating, after going to the toilet, or when your hands become
dirty with respiratory secretions after coughing or
sneezing).
If you have a cough or a runny nose, use a mask.
Cover your mouth with tissue paper and discard the
used tissue when coughing or sneezing; if you're sick, get
medical attention immediately.
Discourage them from sharing their meals or personal
hygiene supplies.
Avoid physical interaction such as handshaking and
facial contact.
Personal hygiene is required for all researchers.
All clinicians will wash their hands after using the
restroom and urinal.
Maintain short, clean nails and avoid facial hair
crossing the seal of the respirator mask.
Personal items should be kept in lockers by all workers.
Please store your items in the visiting lockers.
The clinicians must wash their mouths and hands after
the meal/tea.
Research significance
The consequences of omicron have disrupted research
efforts and current research programs worldwide,
including in the United States and India. As explained
below, several precautions and scientific considerations
must be considered in the omicron scenarios.
• General guidelines with specifications and description
data [87].
Always maintain a social distance of at least one meter
with other humans in all directions.
Minimal touch with the article and human; no
handshake.
Sanitize your hands as much as possible.
Do not use another person's laptop, mobile phone, or
desktop.
Conducting online meetings from a workstation using
a laptop or a mobile device.
Do not use the meeting room for any meetings.
All employees will be informed that they will be under
CCTV surveillance to monitor the above guidelines,
and any non-compliance will be reported.
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• During transit [88].
Using a mask and starting from home.
It is best to work while keeping a social distance.
Say nothing until absolutely required.
It is better not to bring food or other goods from home
to work.
• During entry [88].
After exiting your vehicle, keep social distance.
Keeping track of visitors' names, addresses, ages, and
contact information.
Undertake a thermal screening with an OHC
representative.
Hand sanitizing with sanitizer.
Guideline end-user
Our preventive measures include researchers,
scientists, academics and doctors working in hospitals and
healthcare sectors. The measures also target healthy
members of the community, public health officials and
anyone interested in managing the coronavirus pandemic,
in whatever capacity they act if it is considered acceptable
and beneficial. For reasons of safety and prevention, the
precautions mentioned above must therefore be followed
when attending any kind of academic or research meeting
during a pandemic period.
• During the meeting or event [88].
The simplest method to accomplish this is to advice or
inform participants about omicron and the procedures
taken to ensure their safety.
Encourage everyone to wash their hands often or use
rubbing alcohol.
Coughing or sneezing should be covered with a bent
elbow or a handkerchief.
Providing closed trash cans and wipes to dispose of
them.
Hand massagers with alcohol were conspicuously
exhibited around the premises.
Keep windows and doors open to provide proper
ventilation during your performance.
Providing a mask so they may safely return home or
transport them to a recognized assessment facility.
• Before a meeting or event [87].
Initially, identify and validate communication routes
with key partners like public health and healthcare
professionals.
Ensure you have enough tissues, masks, and hand
sanitizer for everyone attending.
Ensure that all event organizers, participants, vendors,
and visitors provide contact information, including
mobile phone numbers, email addresses, as well as
event locations.
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Conclusions
Omicron is the most-mutated VOC in many countries.
Science, research, and technology are progressing at the
same level as the pandemic due to improved diagnosis,
targeted vaccines, and medical treatments. However,
further studies are needed to improve the understanding of
viral pathogenesis, which may lead to better prevention and
treatment measures. The CDC has cooperated with
commercial labs and universities to perform genetic
surveillance research. To develop a scientifically valid plan
to prevent COVID-19, the WHO advises that countries
increase their research infrastructure. For clinical and
surgical trainees globally, COVID-19 has imposed several
scientific restrictions. The state-wide lockdown has had a
particularly negative impact on basic science research.
Clinicians experienced comparable difficulties due to the
suspension of healthcare services and a sudden return to
full-time responsibilities.
Institutions should take more preventive measures to
stop the spread of COVID-19 now and in the future.
Students, Ph.D. researchers and teachers should often
connect using email and university internet services. The
mental health of students, faculty and staff at a university
should be a priority, as should their safety on campus. It
is the responsibility of the government as well as
the individual institutions to provide food and
accommodation for students traveling from other states or
nations. The different impacts of the pandemic and the
additional difficulties generated by the modified
strains must be overcome, and ensuring equal access to
healthcare is essential. Major global events have a
profound impact on science, and overcoming these
academic challenges require dedicated investigation.
Finally, people will still be able to stop the spread of the
disease by wearing masks, staying away from public places
and getting vaccinated.
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